<DOC>
	<DOC>NCT00004815</DOC>
	<brief_summary>OBJECTIVES: I. Assess the safety and efficacy of recombinant human insulin-like growth factor 1 in a patient with Werner's syndrome and osteoporosis.</brief_summary>
	<brief_title>Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE: The patient receives subcutaneous recombinant human insulin-like growth factor 1 daily for 7 months. The dose is adjusted according to the serum hormone level and biological markers of bone turnover. Concurrent therapy includes a metabolic diet, calcium citrate, and estradiol.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Werner Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Werner's syndrome with osteoporosis and low serum insulinlike growth factor 1 level Patient treated on protocol 049215300 "Metabolic and Skeletal Effects of Exogenous Recombinant Human InsulinLike Growth Factor"</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>Werner's syndrome</keyword>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>rare disease</keyword>
</DOC>